Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive ยท Last trade price on Jan 6, 2026
Cidara Therapeutics Employees
Cidara Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 31 or 44.93% compared to the previous year.
Employees
38
Change (1Y)
-31
Growth (1Y)
-44.93%
Revenue / Employee
n/a
Profits / Employee
-$4,861,526
Market Cap
6.97B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 38 | -31 | -44.93% | 38 | 0 |
| Dec 31, 2023 | 69 | -4 | -5.48% | 69 | 0 |
| Dec 31, 2022 | 73 | -16 | -17.98% | 73 | 0 |
| Dec 31, 2021 | 89 | 9 | 11.25% | 89 | 0 |
| Dec 31, 2020 | 80 | 12 | 17.65% | 79 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
CDTX News
- 12 months ago - Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - GlobeNewsWire
- 1 year ago - Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 - Forbes
- 1 year ago - Merck expects over $5 billion commercial opportunity from Cidara's flu drug - Reuters
- 1 year ago - Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX - Business Wire
- 1 year ago - This Biotech's Stock Price More Than Doubled on Friday. Here's Why. - Investopedia
- 1 year ago - This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy - Market Watch
- 1 year ago - Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches - Invezz
- 1 year ago - Merck to Buy Cidara Therapeutics in $9.2 Billion Deal - WSJ